The case for & against
Bull & Bear analysis
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is an emerging leader in the synthetic biology sector, operating primarily in the field of cell programming and biomanufacturing. The company focuses on developing engineering platform technology, enabling it to rapidly design and produce microbes for diverse applications across various industries, including pharmaceuticals, agriculture, and food production. Ginkgo is strategically positioning itself in the growing biomanufacturing space with its autonomous laboratory systems, enhancing efficiency and scalability in genomic research and protein production.
Bull says
- ↑Secured MIT and Caltech agreements to scale autonomous lab network
- ↑Partnered with Acies Bio to commercialize high-performance Aspergillus niger strains
- ↑High liquidity holdings should sustain operations despite cash burn
- ↑Government contracts bolster credibility and market visibility
- ↑Book-to-price ratio above 1 and balanced leverage indicate value
- ↑Elevated short interest could trigger a short-covering rally
Bear says
- ↓Q2 revenue fell 48% YoY to $20M, signaling demand challenges
- ↓Net loss expanded to $57M and cash burn reached $45M, straining liquidity
- ↓High volatility risk may deter investors amid unpredictable price swings
- ↓Weak profitability metrics and negative earnings yield highlight return struggles
- ↓Low institutional ownership indicates limited confidence from major investors
- ↓Negative growth factor and low quant score underline structural concerns
Investment themes with DNA
Stocks with high short interest ratios
Stocks with highest short interest
Stocks recommended for short-selling opportunities
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- 2026, our focus will be on investing to win the category of autonomous labs, and I'm really excited, even since we just spoke a few months ago, this category has really been growing in attention.
- I think this is a really nice, as I talked about last time, opportunity both for Ginkgo to keep our focus on the autonomous labs and for the team at Perimeter to grow under their own brand with a new set of defense tech focused investors.
- $373 million with no bank debt as of Q1 2026.
Bear points
- But you know, there's a big motion right now where, uh, we're seeing an increasing amount of drug discovery work moving to China, uh, from Kendall square was talking about earlier here in the Boston area. And that's because simply Chinese scientists are paid a third as much and they're doing equal work to what's happening here in the US.
- Revenue was $19 million in the first quarter of 2026, down 49% compared to the first quarter of 2025.
- Net loss from continuing operations was $76 million in the first quarter of 2026, compared to a loss of $83 million in the prior year period.